Evaluasi Pengaruh Kebijakan Restriksi Antibiotik Terhadap Penggunaan Antibiotik Karbapenem
Keywords:
Antibiotik Karbapenem, Kebijakan Restriksi Antibiotik, MeropenemAbstract
Penelitian ini bertujuan untuk mengevaluasi kerasionalan penggunaan antibiotik karbapenem sebelum dan setelah adanya kebijakan restriksi antibiotik. Penelitian ini merupakan penelitian obseravsional dengan desain pre-post. Pengumpulan data dilakukan secara retrospektif dan prospektif pada pasien rawat inap yang mendapatkan antibiotik golongan karbapenem di Rumah Sakit X. Penelitian dilakukan di Rumah Sakit X pada semua ruang perawatan, yaitu ruang perawatan umum, ICU (Intensive Care Unit), dan HCU (High Care Unit). Populasi penelitian adalah semua pasien rawat inap di rumah sakit. Sampel penelitian adalah total sampling dari pasien yang memenuhi kriteria inklusi dan ekslusi. Pengumpulan data secara prospektif dilakukan selama periode Januari – Maret 2018 dan data restrospektif pada periode Juni – Agustus 2017. Data diperoleh dari rekam medik pasien. Hasil penelitian menunjukkan bahwa antibiotik golongan karbapenem yang paling banyak digunakan adalah meropenem, angka penggunaan meropenem sebagai terapi antibiotik definitif menjadi meningkat setelah adanya penerapan restriksi. Kesimpulan penelitian yaitu terjadi peningkatan kerasionalan penggunaan antibiotika karbapenem yaitu antibiotik meropenem banyak digunakan sebagai terapi definitif dari 60% sebelum restriksi menjadi 100% setelah restriksi. Penggunaan secara empiris sebelum restriksi sebesar 9,67%, dan setelah restriksi sebesar 57,57%.
References
Djer MM, Indawati W, Hidayati EL, Sjakti HA, Soesanti F. Prosiding Simposium LXXIV A to Z about infections Pediatric antibiotic stewardship : How to prevent of antibiotic resistance? 2018;(April):1–203.
Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant Staphylococcus aureus (VRSA) in methicillin resistant S. aureus (MRSA) strains isolated from burn wound infections. Tzu Chi Medical Journal. 2016;28(2):49–53.
Malang RSUDDrSA. Panduan Pengendalian Multidrug-Resistent Organism (MDRO). 2016;
Sengupta S, Chattopadhyay M. Antibiotic resistance of bacteria: A global challenge. Resonance: Journal of Science Education. 2012;17(2):179.
Sulistia Gan Gunawan dkk. Farmakologi Dan Terapi. Departemen Farmakologi dan Terapeutik. 6th ed. Fakultas Kedokteran Universitas Indonesia; 2016. 594 p.
Infeksi I, Mdro M resistant O, Care I, Nicu U, Soeradji R, Klaten T. Pada Pasien Yang Dirawat Di Bangsal Neonatal Intensive Care Unit ( Nicu ) Rumah Sakit Identification of Multidrug-Resistant Organisms Infection in Neonatal. Jurnal Manajemen dan Pelayanan Farmasi IDENTIFIKASI. 2013;6:243–8.
Departemen Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonsesia Nomor 2046/MENKE/PER/XII/201. Pedoman Umum Penggunaan Antibiotik. 2011;
Kempf M, Cavallo J didier, Chomarat M, Dubreuil L, Maugein J, Muller-serieys C, et al. Comparative in vitro activity of Meropenem , Imipenem and Piperacillin / tazobactam against 1071 clinical isolates using 2 different methods : a French multicentre study. BMC Infect Dis. 2010;10(72):1–9.
Ilvcoooooo SM. Health, United States, 2015. US Department of Health and Human Services. 2015;(DHHS Publication No. 2016-1232).
Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF. Prevalence and characterization of carbapenem-resistant enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS ONE. 2015;10(8):1–11.
Frieden, Tom.Dr, MD M. Antibiotic Resistance Threats. CDC. 2013;22–50.
Halim S V., Yulia R, Setiawan E. Carbapenem Utilization among Adults Inpatients in One Private Hospital in Surabaya. Indonesian Journal of Clinical Pharmacy. 2017;6(4):267–81.
Johnston D, Khan R, Miot J, Moch S, van Deventer Y, Richards G. Usage of antibiotics in the intensive care units of an academic tertiary-level hospital. Southern African Journal of Infectious Diseases. 2018;33(4):106–13.
Media J, Kesehatan A. Issn : 2621-9557. 2019;10(2):152–62.
Nahtigal Klevišar M, Lusa L, Terzić S, Mueller-Premru M, Pirš M, Stupica D. Could we Spare Carbapenems for Empiric Therapy in ESBL-Enterobacteriaceae Colonized Elderly with Community-Onset Sepsis? Journal of Geriatric Medicine and Gerontology. 2019;5(1).
Kiratisin P, Keel RA, Nicolau DP. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. International Journal of Antimicrobial Agents. 2013;41(1):47–51.
Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials. Medicine (United States). 2019;98(51).
Cook PP, Gooch M, Rizzo S. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: A 10-year study. Antimicrobial Agents and Chemotherapy. 2011;55(12):5597–601.
Scholze K, Wenke M, Schierholz R, Groß U, Bader O, Zimmermann O, et al. The Reduction in Antibiotic Use in Hospitals. Deutsches Aerzteblatt Online. 2015;2011(December 2013).
Boel J, Andreasen V, Jarløv JO, Østergaard C, Gjørup I, Bøggild N, et al. Impact of antibiotic restriction on resistance levels of Escherichia coli: A controlled interrupted time series study of a hospital-wide antibiotic stewardship programme. Journal of Antimicrobial Chemotherapy. 2016;71(7):2047–51.
Published
How to Cite
Issue
Section
Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.
Poltekita : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-Share Alike 4.0 International License
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
